Artrya Advances U.S. Commercial Rollout as Salix Flow FDA Submission Nears
Artrya Limited (ASX: AYA) has reported continued progress in commercialising its Salix® AI-powered platform across the United States, with Tanner Health now routinely using the platform in clinical practice and Northeast Georgia Health System becoming its second revenue-generating customer following deployment in July 2026. Cone Health also continues progressing towards clinical implementation, while Artrya is expanding reimbursement workflows to support faster customer adoption and scalable commercial deployment. During the quarter, the Company completed validation activities for its Salix® Coronary Flow module after securing the required U.S. clinical datasets, with FDA submission now imminent and commercial launch targeted for the second half of calendar 2026. Artrya also commenced the SAPPHIRE Study, advanced the formation of its Clinical Advisory Board and expanded commercial discussions with participating U.S. health systems. The Company finished the quarter with a pro forma cash position of AU$74.0 million, providing funding to support ongoing commercial expansion and product development.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Artrya Advances U.S. Commercial Rollout as Salix Flow FDA Submission Nears
Artrya Limited (ASX: AYA) has reported continued progress in commercialising its Salix® AI-powered platform across the United States, with Tanner Health now routinely using the platform in clinical practice and Northeast Georgia Health System becoming its second revenue-generating customer following deployment in July 2026. Cone Health also continues progressing towards clinical implementation, while Artrya is expanding reimbursement workflows to support faster customer adoption and scalable commercial deployment. During the quarter, the Company completed validation activities for its Salix® Coronary Flow module after securing the required U.S. clinical datasets, with FDA submission now imminent and commercial launch targeted for the second half of calendar 2026. Artrya also commenced the SAPPHIRE Study, advanced the formation of its Clinical Advisory Board and expanded commercial discussions with participating U.S. health systems. The Company finished the quarter with a pro forma cash position of AU$74.0 million, providing funding to support ongoing commercial expansion and product development.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au